Prognostic impact of KRAS and BRAF^V600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab:  NCCTG N0147 (Alliance).

Authors

Frank A. Sinicrope

Mayo Clinic, Rochester, MN

Frank A. Sinicrope , Michelle R. Mahoney , Thomas C. Smyrk , Stephen N. Thibodeau , Richard M. Goldberg , Garth D. Nelson , Daniel J. Sargent , Steven R. Alberts

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.

First Author: Aziz Zaanan

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.

First Author: Julien Taïeb

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

First Author: S. R. Alberts

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).

First Author: Frank A. Sinicrope